by Clinical Neuropsychologist Online | Saturday, August 3, 2024 | Dementia
Abstract INTRODUCTION We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). METHODS We...
by Clinical Neuropsychologist Online | Saturday, August 3, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Timothy Daly, Kasper P. Kepp, Bruno P. Imbimbo | August 3, 2024...
by Clinical Neuropsychologist Online | Friday, August 2, 2024 | Dementia
Abstract INTRODUCTION Triggering receptor expressed on myeloid cells 2 (TREM2) agonists are being clinically evaluated as disease-modifying therapeutics for Alzheimer’s disease. Clinically translatable pharmacodynamic (PD) biomarkers are needed to confirm drug...
by Clinical Neuropsychologist Online | Thursday, August 1, 2024 | Dementia
Abstract INTRODUCTION We disclosed amyloid positron emission tomography (PET) results in individuals with subjective cognitive decline (SCD) and studied patient experiences and outcomes over a 6-month period. METHODS Fifty-seven participants from the Subjective...
by Clinical Neuropsychologist Online | Thursday, August 1, 2024 | Dementia
Abstract INTRODUCTION In Down syndrome (DS), white matter hyperintensities (WMHs) are highly prevalent, yet their topography and association with sociodemographic data and Alzheimer’s disease (AD) biomarkers remain largely unexplored. METHODS In 261 DS adults...
